These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 30130255)

  • 1. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
    Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
    J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 3. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.
    Läubli H; Varki A
    Cell Mol Life Sci; 2020 Feb; 77(4):593-605. PubMed ID: 31485715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
    Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells.
    Jia Y; Yu H; Fernandes SM; Wei Y; Gonzalez-Gil A; Motari MG; Vajn K; Stevens WW; Peters AT; Bochner BS; Kern RC; Schleimer RP; Schnaar RL
    J Allergy Clin Immunol; 2015 Mar; 135(3):799-810.e7. PubMed ID: 25747723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.
    Läubli H; Alisson-Silva F; Stanczak MA; Siddiqui SS; Deng L; Verhagen A; Varki N; Varki A
    J Biol Chem; 2014 Nov; 289(48):33481-91. PubMed ID: 25320078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human sialoglycan ligands for immune inhibitory Siglecs.
    Gonzalez-Gil A; Li TA; Kim J; Schnaar RL
    Mol Aspects Med; 2023 Apr; 90():101110. PubMed ID: 35965135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
    Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viewing Siglecs through the lens of tumor immunology.
    Fraschilla I; Pillai S
    Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
    Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
    Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
    Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
    Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression.
    Schleimer RP; Schnaar RL; Bochner BS
    Curr Opin Allergy Clin Immunol; 2016 Feb; 16(1):24-30. PubMed ID: 26694037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties.
    Yu H; Gonzalez-Gil A; Wei Y; Fernandes SM; Porell RN; Vajn K; Paulson JC; Nycholat CM; Schnaar RL
    Glycobiology; 2017 Jul; 27(7):657-668. PubMed ID: 28369504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
    Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
    J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
    Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
    Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates.
    Padler-Karavani V; Hurtado-Ziola N; Chang YC; Sonnenburg JL; Ronaghy A; Yu H; Verhagen A; Nizet V; Chen X; Varki N; Varki A; Angata T
    FASEB J; 2014 Mar; 28(3):1280-93. PubMed ID: 24308974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.